RVMD FY 2024 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$690M

Net Income

-$600M

EPS (Diluted)

$-3.58

Cash Flow

Operating Cash Flow

-$557M

Free Cash Flow

-$568M

Stock-Based Comp.

$79M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$293M

Stockholders' Equity

$2.3B

Cash & Equivalents

$543M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$12M	-100.0%
Gross Profit	$0	$12M	-100.0%
Operating Income	-$690M	-$487M	-41.5%
Net Income	-$600M	-$436M	-37.5%